Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AREDS2

This article was originally published in The Tan Sheet

Executive Summary

Nearly 100 centers working on an NIH study on the effects of antioxidants and fish oil on progression of age-related macular degeneration seek 4,000 people ages 50 to 85 with AMD to participate, according to an Oct. 12 announcement. The National Eye Institute, which says nearly 2 mil. people in the U.S. suffer from vision loss due to advanced AMD and 7 mil. with AMD are at "substantial risk," expects the Age-Related Eye Disease Study 2 (AREDS2) to build upon results from the first AREDS data released in 2001 (1"The Tan Sheet" Oct. 15, 2001, p. 3). Those results showed high-dose antioxidant vitamins and minerals (vitamins C and E, beta-carotene, zinc, and copper) reduced the risk of progression to advanced AMD by 25%, and the risk of moderate vision loss by 19%. Results of a separate study published this year showed higher intake of omega-3 fatty acids could have prevented an estimated 22% of the cases of AMD (2"The Tan Sheet" July 17, 2006, p 9). DSM will supply the supplements for AREDS2...
Advertisement

Related Content

Vitamin Therapy Cost-Effective In Treating Macular Degeneration – Study
High Omega-3 Intake Protective Against Age-Related Macular Degeneration
Bausch & Lomb OcuVite Line Extension Used In Natl. Eye Institute Study
Bausch & Lomb OcuVite Line Extension Used In Natl. Eye Institute Study

Topics

Advertisement
UsernamePublicRestriction

Register

PS099861

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel